Taxol

Phase 2Small molecule

Bristol-Myers Squibb

Taxol is one of 73 small molecule programs targeting Solid Tumor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorRecruiting

Esophageal AdenocarcinomaActive, not recruiting

Solid TumorPhase 1

Recruiting

Esophageal AdenocarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

3 2

Nubeqa

Bayer

Preclinical

2 3

Fludara

Sanofi

Preclinical

1 4

DATROWAY

Daiichi Sankyo

Preclinical

1 5

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 6

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

2 7

Taxol

Bristol-Myers Squibb

Phase 2

1 8

Proleukin

IIovance Biotherapeutics, Inc.

Preclinical

1 9

Navmi

SSummit Therapeutics

Preclinical

1 10

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Recruiting

Solid Tumor

NCT06839105

Clinical

Trials by Indication[1]

Breast Cancer7 trials

Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00038402·74 enrolled

Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer

Completed·—·Phase 2·NCT00136539·41 enrolled

Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2

Completed·NNSABP Foundation Inc·Phase 3·NCT00004067·2,130 enrolled

Show 4 more trials

Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer

Terminated·AAchieve Life Sciences·Phase 3·NCT00251095·821 enrolled

Neoadjuvant Effect of Albumin Binding Paclitaxel Compared With Common Paclitaxel in Breast Cancer：an Observational Single Center Study of Clinical Efficacy in Adjuvant Chemotherapy

Unknown status·MMei Zhang··NCT05636644·112 enrolled

A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN)

Completed·GGBG Forschungs GmbH·Phase 3·NCT00196872·3,000 enrolled

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00394251·197 enrolled

Non-Small Cell Lung Cancer3 trials

Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research

Unknown status·NNanjing NingQi Medicine Science and Technology Co., Ltd.·Phase 4·NCT02513355·400 enrolled

A Clinical Research of NK Cell Infusion Combined With Chemotherapy in the Treatment of Non-small Cell Lung Cancer

Unknown status·SSouthwest Hospital, China·Phase 2·NCT02734524·104 enrolled

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

Terminated·NNorthwestern University·Phase 1/2·NCT00004093·36 enrolled

Small Cell Lung Cancer2 trials

A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

Withdrawn·GGU Research Network, LLC·Phase 2·NCT02662634

Study of an Early Change of a Chemotherapeutic Doublet Versus Four Cycles of Chemotherapy in Advanced Non Small Cell Lung Cancer

Completed·UUniversity Hospital, Limoges·Phase 2·NCT00199758·227 enrolled

Ovarian Cancer2 trials

A Phase I Study of Taxol, Cisplatin, Cyclophosphamide and Granulocyte Colony-Stimulating Factor (G-CSF) in Previously Nontreated Ovarian Cancer Patients

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00001272·60 enrolled

Study of Paclitaxel in Patients With Ovarian Cancer

Completed·OOasmia Pharmaceutical AB·Phase 3·NCT00989131·789 enrolled

Prostate Adenocarcinoma1 trial

Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00038168·14 enrolled

9 more indications

Esophageal Adenocarcinoma1 trial

Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma

Active, not recruiting·WWeill Medical College of Cornell University·Phase 2·NCT02998268·42 enrolled

Radiotherapy1 trial

Phase II Trial of Pulsed Taxol With Concurrent Thoracic Radiotherapy, & Adjuvant Chemo in Stage III NSCLC

Terminated·LLeo W. Jenkins Cancer Center·Phase 2·NCT00449657·24 enrolled

Lung Cancer1 trial

Chemotherapy and Proton Radiation for the Treatment of Locally Advanced Lung Cancer

Terminated·LLoma Linda University·Phase 1/2·NCT00614484·28 enrolled

Gastric Cancer1 trial

Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer

Unknown status·FFudan University·Phase 2·NCT02072317·140 enrolled

Chemotherapy1 trial

Phase I/II Study of Paclitaxel Plus CPT-11 in Pts. With 2nd Line Chemotherapy of Inoperable or Recurrent GC.

Withdrawn·HHokkaido Gastrointestinal Cancer Study Group·Phase 1/2·NCT00209612·40 enrolled

Cervical Cancer1 trial

Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer

Unknown status·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 2·NCT04238988·45 enrolled

Head and Neck Cancer1 trial

EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH HEAD AND NECK CANCER.(GCC 0202)

Completed·MMohan Suntharalingam·Phase 2·NCT00270790·21 enrolled

Paclitaxel1 trial

A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian

Terminated·OOncoMed Pharmaceuticals, Inc.·Phase 1·NCT01952249·20 enrolled

Solid Tumor1 trial

A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AWT020 Alone and in Combination With Other Antitumor Therapies in Patients With Advanced Malignancies

Recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 1·NCT06839105·214 enrolled

Sources

References

[1]
ClinicalTrials.gov — 24 trial records for Taxol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Taxol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Taxol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Bristol-Myers Squibb

Taxol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Breast Cancer7 trials

Non-Small Cell Lung Cancer3 trials

Small Cell Lung Cancer2 trials

Ovarian Cancer2 trials

Prostate Adenocarcinoma1 trial

Esophageal Adenocarcinoma1 trial

Radiotherapy1 trial

Lung Cancer1 trial

Gastric Cancer1 trial

Chemotherapy1 trial

Cervical Cancer1 trial

Head and Neck Cancer1 trial

Paclitaxel1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News